Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s share price dropped 2.8% on Wednesday . The stock traded as low as $8.16 and last traded at $8.26. Approximately 334,673 shares were traded during mid-day trading, a decline of 1% from the average daily volume of 337,931 shares. The stock had previously closed at $8.50.
Silverback Therapeutics Stock Performance
The company has a market cap of $297.84 million, a P/E ratio of -3.41 and a beta of 0.60. The firm’s fifty day moving average is $8.80 and its two-hundred day moving average is $6.35.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Stories
- Five stocks we like better than Silverback Therapeutics
- What Investors Need to Know About Upcoming IPOs
- High-Yield Texas Instruments Could Hit New Highs Soon
- CD Calculator: Certificate of Deposit Calculator
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is a buyback in stocks? A comprehensive guide for investors
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
